文献检索
文档翻译
深度研究
Zotero 插件
邀请有礼
套餐&价格
历史记录
Suppr
超能文献
应用&插件
文献AI研究员
20分钟写一篇综述,助力文献阅读效率提升50倍。
立即体验
用中文搜PubMed
大模型驱动的PubMed中文搜索引擎
马上搜索
文档翻译
学术文献翻译模型,支持多种主流文档格式。
立即体验
应用&插件
Zotero 插件
浏览器插件
Mac 客户端
Windows 客户端
微信小程序
定价
高级版会员
购买积分包
购买API积分包
服务
文献检索
文档翻译
深度研究
API 文档
关于我们
关于 Suppr
公司介绍
联系我们
用户协议
隐私条款
关注我们
Suppr 超能文献
核心技术专利:
CN118964589B
侵权必究
粤ICP备2023148730 号-1
Suppr @ 2025
Remicade approved for children with Crohn's disease.
出版信息
FDA Consum. 2006 Jul-Aug;40(4):6.
PMID:
17245830
Abstract
摘要
相似文献
1
Remicade approved for children with Crohn's disease.
FDA Consum. 2006 Jul-Aug;40(4):6.
2
FDA approves Cimzia to treat Crohn's disease.
Gastroenterology. 2008 Jun;134(7):1819. doi: 10.1053/j.gastro.2008.04.034. Epub 2008 May 12.
3
Complications of infliximab therapy in children and adolescents affected by Crohn's disease.
Am J Gastroenterol. 2003 Dec;98(12):2812-3. doi: 10.1111/j.1572-0241.2003.08757.x.
4
Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
Prescrire Int. 2007 Oct;16(91):194.
5
[What can be expected from biological therapies for Crohn's disease?].
Gastroenterol Clin Biol. 2001 Nov;25(11):945-7.
6
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
Am J Gastroenterol. 2005 Jul;100(7):1435-8. doi: 10.1111/j.1572-0241.2005.50622_2.x.
7
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Am J Gastroenterol. 2005 Jul;100(7):1433-5. doi: 10.1111/j.1572-0241.2005.50622_1.x.
8
[Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
Z Gastroenterol. 2009 Feb;47(2):240-2. doi: 10.1055/s-0028-1109073. Epub 2009 Feb 5.
9
Re: Fefferman et al.--"Recurrence" of chronic pancreatitis appearing on a patient with underlying Crohn's disease.
Am J Gastroenterol. 2002 Mar;97(3):761-2. doi: 10.1111/j.1572-0241.2002.05567.x.
10
Toxicity of infliximab in the course of treatment of Crohn's disease.
Expert Opin Drug Saf. 2006 Jan;5(1):9-16. doi: 10.1517/14740338.5.1.9.